Ventyx biosciences reports fourth quarter and full year 2022 financial results and highlights recent corporate progress

Phase 2 trials of vtx958 (tyk2 inhibitor) are ongoing in plaque psoriasis, crohn's disease and psoriatic arthritis, with topline phase 2 data in plaque psoriasis expected in q4 2023
VTYX Ratings Summary
VTYX Quant Ranking